Clinical Trials · NCT05268237
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
- Phase
- Phase 1/Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Biolingus
- Enrollment
- 15
- Start date
- Apr 2023
- Locations
- 1 site, Hong Kong
- Primary endpoint
- Incidence, nature and severity of adverse events